Question Bank › Demand pull is outrunning the plan for one still

Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing…

Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it

Calls Tested
487
Answered YES
7
Hit Rate
1.4%
rare by design

Surmodics, Inc. (SRDX) — this company's answers

NO on the Q3 2018 call 2018-08-06 A
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes an offering with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. The offering must be small relative to total business. Let's examine the transcript. Management discusses several products: SurVeil DCB (with Abbott), thrombectomy platform (Embolitech), .014 and .018 balloons, Telemark microcatheter, IVD products. Also clinical trials. Look for language about demand exceeding preparation. For example, for Telemark microcatheter: "Early clinician feedback in cases treating patients continues to be overwhelmingly positive." But that's feedback, not necessarily orders or uptake ahead of preparation. For .014 balloon: "encouraging clinician feedback" but no mention of demand exceeding supply. For SurVeil: they have agreement with Abbott, revenue recognized. But that's a partnership, not a small offering. For thrombectomy: they are developing, not yet commercial. For IVD: they launched MatrixGuard Diluent, but no mention of demand exceeding preparation. Check for any specific mention of "ahead of" or "exceeded" or "more than expected" regarding customer response. The transcript says: "Our results reflect solid top-line performance and operational results as we continue to invest in our new product pipeline." Not specific. Also: "We are pleased to report strong operating performance" but that's overall. Look for any statement about a product selling out or capacity. None. The only possible candidate might be the .014 balloon or Telemark, but management only says "encouraging clinician feedback" and "overwhelmingly positive" but no mention of running ahead of preparation. Also no mention of concrete steps to expand capacity or investment in response to demand. The company did increase revenue guidance, but that's overall, not specific offering. Thus, answer NO. Also note: The question asks for both halves about the SAME identifiable offering. No such offering is described. Therefore, answer NO.

← Back to the full SRDX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe ONE identifiable offering or initiative of the company — a product, service, program, format, capability, market, or line of business that is still a clearly smaller part of the company's overall results today — for which BOTH of the following are conveyed in management's own words as a present-tense reality: (1) CUSTOMER RESPONSE IS RUNNING AHEAD OF WHAT THE COMPANY HAD PREPARED FOR. Management indicates that real, current uptake of this offering — actual orders, sign-ups, bookings, volumes, enrollments, deployments, sell-through, or usage happening now — is stronger, faster, or broader than the company had planned, staffed, stocked, built, or budgeted for. This may come through in many forms fitting the business: demand exceeding what was allocated to it, the offering selling out or running ahead of supply or capacity set aside for it, adoption outpacing the rollout schedule, interest arriving from more customers or channels than the plan assumed, or management plainly saying the response has exceeded what they anticipated when they sized the effort. What matters is a described gap between the customer response actually arriving and the scale the company had prepared — grounded in current activity, not in hopes or projections. (2) THE COMPANY IS RESPONDING RIGHT NOW BY PUTTING MORE OF ITSELF BEHIND IT. Management describes concrete steps already underway — not merely planned — to enlarge the company's commitment to this same offering: adding capacity, production, inventory, locations, staff, or investment dedicated to it; accelerating or broadening its rollout; reallocating people, capital, or capacity toward it from elsewhere; or moving up timelines because of the response. The response should be described as in motion in the current period. Answer YES only when both halves are present about the SAME identifiable offering, and that offering is still small relative to the company's total business, so the reported results reflect only the beginning of its contribution. Answer NO if the strong uptake described is simply the company's main established business performing well; NO if the offering's momentum is described only through pipeline, interest, or expectations rather than current real uptake; NO if the company is not described as taking concrete steps now to expand behind it; NO if the expansion steps are only under consideration or scheduled for the future; NO if the demand-ahead-of-plan framing refers only to a quarterly financial beat rather than to a specific offering outrunning the company's preparation for it; NO if the initiative is being expanded defensively to offset weakness elsewhere rather than in response to its own demand; and NO if the dynamic appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
HCKT The Hackett Group, Inc. Q1 2024 2024-05-08 C
ROCK Gibraltar Industries, Inc. Q1 2024 2024-05-01 B+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
SYY Sysco Corporation Q1 2023 2022-11-01 C+
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+

How the model reasoned

HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).

More from the question bank

Said-then-did: management reports back on itManagement is buying/committing capital at aManagement is re-underwriting a specific assEvent-dense runwaySecond engine igniting off the firstEveryday buyers, repeat needAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.